Status:
COMPLETED
Use of Somatropin in Turner Syndrome
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Genetic Disorder
Turner Syndrome
Eligibility:
FEMALE
2-11 years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.
Eligibility Criteria
Inclusion
- Turner Syndrome
- Not previously treated with growth hormone or androgen
- Well-documented height over the previous 12 months
- Informed consent of parents (and child if appropriate)
Exclusion
- Growth hormone (GH) deficiency based on a GH stimulation test
Key Trial Info
Start Date :
September 14 1987
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 11 2004
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT01518036
Start Date
September 14 1987
End Date
April 11 2004
Last Update
February 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Crawley, United Kingdom, RH11 9RT